The DOACs appear to be more effective than vitamin K antagonists (VKAs) in patients over 65 years of age with newly diagnosed atrial fibrillation, research shows. They have a slightly lower risk of cerebral infarction and systemic embolism. In addition, DOACs appear safer than VKAs: the risk of serious bleeding and intracranial bleeding appears to be slightly lower.
The preference for DOAC treatment applies to non-frail patients. There is no explicit preference for a DOAC in vulnerable elderly people, partly because less research has been done in this group. More experience has also been gained with VKAs. Their choice therefore depends on individual characteristics, for example whether there is a contraindication. The NHG advises general practitioners to discuss the advantages and disadvantages of a DOAC or VKA with the patient.
Furthermore, there is no room in the new standard for platelet aggregation inhibitors, such as acetylsalicylic acid and carbasalate calcium, and clopidogrel. These drugs are not useful for atrial fibrillation, the NHG indicates.
2023-10-30 23:00:11
#NHG #preference #DOAC #Pharmaceutisch #Weekblad
/nginx/o/2022/10/29/14928415t1h3027.jpg "Understanding Russian Aggression: Freeze Conflicts, Missile Buys, and Baltic States’ Safety")